Alpha-galactosyl xenoantigen (Galα1,3Gal epitope) (α-Gal)

The α-Gal xenoantigen, specifically the Galα1,3Gal epitope, is a carbohydrate structure formed by the addition of a galactose in an α(1,3)-glycosidic linkage to another galactose, commonly found on proteins and lipids in non-primate mammals[4][6]. Humans lack this epitope due to inactivation of the GGTA1 gene and instead produce natural anti-Gal antibodies. In xenotransplantation, when tissues bearing α-Gal are transplanted into humans, these antibodies recognize and bind the epitope, activating the complement cascade, leading to hyperacute rejection of the graft[1][3][4][6]. Detection and quantification of α-Gal in tissues are crucial for predicting immunogenic risk, and genetic engineering of donor animals to eliminate α-Gal epitopes (GGTA1-knockout pigs) is a key strategy to mitigate immune rejection[1][3][4][6]. The α-Gal epitope also plays a role in experimental cancer immunotherapy and tissue regeneration strategies via designed nanoparticles[1].

Other names

alpha-Gal epitopeGalα1,3GalGal alpha (1,3)Galalpha-galactosyl epitopeα-gal antigenGal antigen

Antibody binding leading to complement activation and immune rejection Fc-receptor binding triggers antigen presentation